Comment
Author: Admin | 2025-04-28
US6943166 (Litigated)Termination or Final Written Decision 27 Oct, 2017 US6943166 (Litigated)Termination or Final Written Decision 03 Oct, 2017 US6943166 (Litigated)Termination or Final Written Decision 16 Aug, 2017 US6943166 (Litigated) While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Cialis and ongoing litigations to help you estimate the early arrival of Cialis generic. Cialis's Litigations Cialis been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 13, 2015, against patent number US7182958. The petitioner Actelion Pharmaceuticals Ltd, challenged the validity of this patent, with ICOS Corporation as the respondent. Click below to track the latest information on how companies are challenging Cialis's patents. Last updated on February 25, 2025 Patent Proceeding Filing Date Status Respondent Petitioner US6943166 June, 2018 Terminated-Denied (07 Dec, 2018) ICOS Corporation Aquestive Therapeutics, Inc. US6943166 July, 2017 Terminated-Settled (27 Oct, 2017) ICOS Corporation Dr. Reddy's Laboratories, Inc. US6943166 July, 2017 Terminated-Settled (03 Oct, 2017) ICOS Corporation Argentum Pharmaceuticals LLC US6943166 November, 2016 Terminated-Settled (16 Aug, 2017) ICOS Corporation Mylan Pharmaceuticals Inc. US6943166 December, 2016 Terminated-Denied (03 Jul, 2017) ICOS Corporation MonoSol Rx, LLC US6943166 February, 2016 Terminated-Denied (01 Sep, 2016) ICOS Corporation IntelGenx Corp. US6821975 January, 2015 FWD Entered (03 Aug, 2016) ICOS Corporation Actelion Pharmaceuticals Ltd US7182958 January, 2015 FWD Entered (03 Aug, 2016) ICOS Corporation Actelion Pharmaceuticals Ltd FDA has granted some exclusivities to Cialis. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Cialis, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Cialis. Exclusivity Information Cialis holds 4 exclusivities. All of its exclusivities have expired in 2021. Details of Cialis's exclusivity codes and their expiration dates are given below. Drug Exclusivity Drug Exclusivity Expiration New Indication(I-641) Oct 06, 2014New Indication(I-642) Oct 06, 2014M(M-219) Feb 15, 2021Pediatric Exclusivity(PED) Aug 15, 2021 Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years. Get the exclusive patent insights now. Don't be the last to know. US patents provide insights into the
Add Comment